Zacks Small Cap Research
Cadrenal Therapeutics Inc. News
Latest updates and market news for CVKD
2 news
Feb 22 - Feb 28, 2026
Page 1
GlobeNewswire
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
📈
AI Sentiment
Highly Positive
8/10
Share this news page